Stock IGC IGC PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News IGC Pharma, Inc.

Equities

IGC

US45408X3089

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.458 USD +6.51% Intraday chart for IGC Pharma, Inc. -6.53% +63.51%
Apr. 16 IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo CI
Mar. 22 Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IGC PHARMA : Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
PU
IGC-AD1'S Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
AQ
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
BU
IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo
CI
IGC Pharma Adds Advisor in Artificial Intelligence
BU
IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K
PU
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
BU
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law
MT
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law
MT
IGC Pharma : Material Agreement - Form 8-K
PU
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited
CI
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
AQ
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
BU
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease
CI
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
BU
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
BU
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors
CI
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
BU
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
BU
IGC Pharma Reports Third Quarter Fiscal 2024 Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGC Stock
  4. News IGC Pharma, Inc.